Glaucoma
Conditions
Interventions
Group 1:Nicotinamide riboside 300mg/day
Group 2:Placebo
Sponsors
Research Fund Secretariat, Food and Health Bureau, The Government of HKSAR
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Aged >= 18 years; best corrected VA >= 20/40; IOP <= 28mmHg; no history of laser procedure or intraocular surgery other than uncomplicated cataract extraction; patients with evidence of progressive RNFL/GCIPL thinning detected by Guided Progression Analysis (GPA) or Trend-based Progression Analysis (TPA).
Exclusion criteria
Exclusion criteria: Pathological myopia; diseases that may cause visual field loss or optic disc abnormalities other than glaucoma; inability to perform reliable visual field; suboptimal quality of OCT images; and diabetic retinopathy/maculopathy; and a history of abnormal liver function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparing the rates of RNFL thinning measured with a swept-source OCT over 24 months of follow-up between the treatment arms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to visual field progression;Time to progressive RNFL/GCIPL thinning;The rates of change of visual field mean deviation and visual sensitivity at individual visual field locations;Changes in visual field mean deviation (MD) and visual sensitivity at individual locations; | — |
Countries
China
Contacts
Public ContactLeung Kai Shun Christopher
Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong
Outcome results
None listed